Commentary: Is Resistance Futile?

  • Danielle Gottlieb Sen
    Address reprint requests to Danielle Gottlieb Sen, MS, MD, MPH, Department of Surgery, Division of Pediatric Cardiac Surgery, Johns Hopkins School of Medicine, Baltimore, MD 21287, (443) 287-1262.
    Department of Surgery, Johns Hopkins School of Medicine, Baltimore, MD
    Search for articles by this author
      Treprostenil improved surgical candidacy for SV patients with high PVR following stage I and stage II. Mechanistic work and clinical trials are needed to establish the benefits of TRE for SV patients.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Seminars in Thoracic and Cardiovascular Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Newburger J.
        • Sleeper L.
        • Hollenbeck-Pringle D.
        • et al.
        Transplant-Free Survival and Interventions at 6 Years in the SVR Trial.
        Circulation. 2018; 137: 2246-2253
        • Pundi K.N.
        • Johnson J.N.
        • Dearani J.A.
        • et al.
        40-Year follow-up after the Fontan operation: long-term outcomes of 1,052 patients.
        J Am Coll Cardiol. 2015; 66: 1700-1710
        • Rochelson E.
        • Richmond M.E.
        • LaPar D.J.
        • et al.
        Identification of risk factors for early Fontan failure.
        Semin Thorac Cardiovasc Surg. 2020; 32: 522-528
        • Weisert M.
        • Menteer J.D.
        • Durazo-Arvizu
        • et al.
        Early prediction of failure to progress in single ventricle palliation: A step toward personalizing care for severe congenital heart disease.
        J Heart Lung Transplant. 2022; ([In Press])
        • Sullivan R.T.
        • Handler S.S.
        • Feinstein J.A.
        • et al.
        Subcutaneous treprostenil improves surgical candidacy for next stage palliation in single ventricle patients with high risk hemodynamics.
        Semin Thorac Cardiovasc Surg. 2022; ([In Press])
        • Jeremiasen I.
        • Tran-Lundmark K.
        • Idris N.
        • et al.
        Pulmonary vasodilator therapy in children with single ventricle physiology: effects on saturation and pulmonary arterial pressure.
        Pediatric Cardiology. 2020; 41: 1651-1659
        • Mori H.
        • Park I.S.
        • Yamagishi H.
        • et al.
        Sildenafil reduces pulmonary vascular resistance in single ventricle physiology.
        International J Cardiology. 2016; 221: 122-127
        • Castaldi B.
        • Bordin G.
        • Padalino M.
        • et al.
        Hemodynamic impact of pulmonary vasodilators on single ventricle physiology.
        Cardiovasc Ther. 2018; 36: e12314

      Linked Article

      • Subcutaneous Treprostinil Improves Surgical Candidacy for Next Stage Palliation in Single Ventricle Patients With High-Risk Hemodynamics
        Seminars in Thoracic and Cardiovascular Surgery
        • Preview
          Single ventricle (SV) patients with pulmonary vascular disease (SV-PVD) are considered poor surgical candidates for Glenn or Fontan palliation. Given limited options for Stage 1 (S1) and Stage 2 (S2) SV patients with SV-PVD, we report on the use of subcutaneous treprostinil (TRE) to treat SV-PVD in this population. This single-center, retrospective cohort study examined SV patients who were not candidates for subsequent surgical palliation due to SV-PVD and were treated with TRE. The primary outcome was ability to progress to the next surgical stage; secondary outcomes included changes in hemodynamics after TRE initiation.
        • Full-Text
        • PDF